SUMMARY Evening dosing has become standard for H2 receptor antagonists, because available agents inhibit nocturnal basal acid secretion more effectively than daytime stimulated secretion. We studied the optimal time of administration of a new high affinity long acting H2 receptor antagonist, SKF 94482, for the suppression of intragastric acidity using intragastric telemetry. Sixteen healthy subjects received SKF 94482 200 mg or placebo at 07 30, 17 30, and 21 30 h during four separate studies. Time (h) above pH 4 was (mean (SD)) 1-1 (1.2) on placebo, 7.8 (5.0) on SKF 94482 given at 0730, 5.75 (3.6) on SKF 94482 given at 1730, and 6.1 (2.9) when given at 21 30. All treatment regimens were effective in increasing time above pH 4 (p<0.01). The efficacy of the morning dose of SKF 94482 indicates that the best time to give H2 receptor antagonists despends on their pharmacological properties.
Since the introduction of cimetidine there has been a constant rationalisation of dose and time of administration of the H2 receptor antagonists. This has resulted from a better appreciation of their effect on intragastric acidity and the role of acid suppression in duodenal ulcer healing. While available H2 receptor antagonists have a profound effect on basal nocturnal acid secretion's they are less effective in the inhibition of naturally stimulated daytime acid.'3 The efficacy of targetting the H2 receptor antagonists to the nocturnal time period has been borne out in individual trials of duodenal ulcer healing67 and by a meta-analysis designed to study the relationship between acid suppression and ulcer healing.' The proton pump blocker omeprazole, however, in doses of 20 mg/day or greater, can achieve higher healing rates than the H2 receptor antagonists, which may result from the addition of daytime to nocturnal acid suppression.'-" The potent prolonged acid suppression of omeprazole is also associated with a significant increase in serum gastrin,'2 which has been the subject of considerable debate'"'6 in view of the possible deleterious consequences. Accepted for publication 16 October 1988.
Using a three dimensional model to explore the relationship between acid suppression and ulcer healing, increasing the duration of suppression -that is, the number of hours spent above any given threshold pH -accelerated the rate of healing up to 16 hours. 7 Thus extending the duration of acid suppression afforded by H2 receptor antagonists beyond the nocturnal period might significantly improve ulcer healing, perhaps without the effect on gastrin from suppression of acid throughout the whole 24 hour period.
SKF 94482 is a new H2 receptor antagonist which in in vitro and animal studies has a high affinity for the H2 receptor and a potent and unusually long duration of action on acid secretion. The drug has a low bioavailability of approximately 7%, a half life of 15-32 hours and when given orally is twice as potent as ranitidine. We studied the optimal time of administration and duration of effect of this new drug by its effect on 24 hour intragastric acidity. Where there was a significant treatment effect, the Student-Newman-Keul's range test was used to make all possible comparisons among treatment groups; significance was assessed at the 1% level. Serum gastrin was not normally distributed, therefore the analysis of gastrin by drug was undertaken using Kruskal-Wallis and Friedman non-parametric statistics.
Methods

Results
All subjects tolerated the medication and procedures well, one subject had a less than two-fold rise in serum alanine transferase on liver function testing, for the three weeks of the study that he took SKF 94482, which returned to normal one week after the end of the study. One study period of the 60 individual study days was lost because of a fault in the recording equipment and was excluded from the analysis.
TWENTY FOUR HOUR ACIDI1Y
The mean of all subjects by treatment is shown as a continuous pH profile in Fig. 1 . Mean 24 hour pH was 1-7 (0.4) on placebo, which was raised to 3-3 (1.0) on treatment following the morning dose; to 3-0 (0.8) with the evening dose and 3-1 (0.7) with the night time dose. All the SKF 94482 regimens were effective (p<0-01) in increasing the time pH was above 4, and raising the mean and median pH when compared with placebo, but no drug regimen was different from another. Summary mean total data are represented graphically as notched box whisker plots (Fig. 2) . Duration of time spent above pH 4 is summarised in the Table. Fig. 2 Notched box whisker plot for 24 hours. Annotation is: the central line is the group median, the box encloses the middle 50% of the data values, the whiskers 1.5 times the interquartile range, outliers beyond this are represented a single points. Notches on the boxes represent the 95% CI on the median ifthe CI is wider than the interquartile range the box has a folded over appearance.
Night
All drug regimens were significantly more effective than placebo (p<001) but did not differ from each other. The mean pH on placebo was 1-6 (0.6) increasing to 3-6 (1.4) with the morning dose, [3] [4] [5] [6] (1.0) with the evening dose, and 4.0 (1.2) with the night time dose. Box whisker plots summarise the data in Fig. 3a .
Morning
All drug regimens were significantly more effective (p<0.01) than placebo (1-84 (0.05)). The morning dose was slightly more effective (3.8 (1.2)) than the other two (2.9 (0.8) evening, 2-9 (0.8) night), p<0-05. Box whisker plots are shown in Fig. 3b .
Afternoon
Only the morning dose (3.2 (1-1)) was significantly different from placebo 1-7 (0.4) (p<0-01). Mean pH for the evening dose was 2.5 (0.6) and for the night dose 2.5 (0.6). Box whisker plots summarise the data in Fig. 3c .
Evening
The morning dose raised pH to 2-5 (0.9) and evening dose to 2-8 (0.7) compared with placebo 1.7 (0.4) (p<0-01), the night time dose showed a significant response at pH 2 1 (0.5) when compared with 
Night
placebo at the 5% level. These data are summarised in Fig. 3d .
The duration of action of SKF 94482 given at any of the three time points is such that a significant effect is seen 14-20 hours after administration. serum gastrin from initial and placebo values and this increase was statistically significant (p<0.01). No single value, however, extended outside our normal range (<180 pg/mI). 
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Fig. 4 Notched box whisker plotfor serum gastrin (pg/ml).
for other H2 receptor antagonists. This drug has a long duration of action, as pH is still significantly raised above that of placebo between 14 and 20 hours after administration. This, together with the efficacy of the morning dose in inhibiting daytime and food stimulated acid secretion suggests that a different therapeutic approach can be taken with this compound compared with existing H2 receptor antagonists. Nocturnal administration of H2 receptor antagonists has led to equivalent or improved healing rates compared with standard regimens in duodenal ulcer'-this has been ascribed to the pharmacological properties of the currently available agents which are most effective in inhibiting the prolonged basal acid secretion occurring at night.' 3 5 When currently available H2 receptor antagonists are given in a single dose the duration of suppression is limited to 10 hours.2-5 Thus there is little effect on daytime acidity after nocturnal dosing. As duration of suppression above a target pH can be correlated with duodenal ulcer healing'7 the greater duration of action of SKF 94482 might be expected to lead to improved healing rates over existing H2 receptor antagonists. Particularly useful might be the effect of addition of good nocturnal acid suppression to the daytime suppression that can be achieved by a single morning dose. Omeprazole, in doses greater than 20 mg od, has a profound effect on intragastric acidity and excellent duodenal ulcer healing rates,9 '°but is associated with hypergastrinaemia. 1 " Perhaps in an attempt to reduce this effect on gastrin, omeprazole is being advocated at a 20 mg dose, this is, however, associated with a much more variable antisecretory response"2 with correspondingly less impressive duodenal ulcer healing rates. '8 There is a gap between the duration of action of famotidine and ranitidine and the higher doses of omeprazole, which allows a potential window for therapy. An agent within this window might give rise to improved healing rates and a reduction in treatment failures without resulting in the two-fold rise in fasting serum gastrin seen with omeprazole.1' Although a complete gastrin response profile was not performed in this study, the fact that no subject had a serum gastrin outside the normal range at the end of one weeks treatment with SKF 94482, would support this contention.
Recent evidence has incriminated postprandial acid reflux rather than nocturnal reflux in the pathogenesis of erosive oesophagitis.'01 "It might therefore be expected that any H2 receptor antagonists with the ability to control daytime acidity effectively might be more effective than conventional H2 receptor antagonists, as has been for omeprazole." '3 The similarly prolonged duration of action of SKF 94482 with its effect on daytime acidity may make this a useful agent in this disease. 
